Tissue factor - a therapeutic target for thrombotic disorders.

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• Tissue Factor (TF) is a transmembrane protein crucial for initiating the coagulation cascade.
• TF exposure or expression, via vascular injury, plaque rupture, sepsis, or cancer, can lead to generalized clotting and thrombosis.
• Targeting TF is a key strategy for antithrombotic therapies.

Purpose of the Study:

• To review current strategies for inhibiting tissue factor (TF) to prevent thrombosis.
• To discuss preclinical and clinical approaches targeting TF expression and function.
• To highlight the potential of local anti-TF agents in managing thrombosis.

Main Methods:

• Inhibiting TF expression using deactivating cytokines (IL-4, -10, -13), prostanoids, signal transduction modifiers (pentoxifylline, retinoic acid, vitamin D3), and antisense oligonucleotides.
• Blocking TF function via antibodies preventing FVIIa binding, active site-inhibited FVIIa, TF/FVIIa complex inhibitors, and TF pathway inhibitor or nematode anticoagulant peptide C2.
• Review of agents that have entered Phase II clinical trials.

Main Results:

• Preclinical studies demonstrate inhibition of TF-induced clotting through various molecular targets.
• TF pathway inhibitor and nematode anticoagulant peptide C2 have advanced to Phase II clinical trials.
• Local administration of anti-TF agents shows potential for site-specific thrombosis prevention with reduced bleeding risk.

Conclusions:

• Inhibiting tissue factor (TF) is a viable therapeutic approach for managing thrombosis.
• Multiple strategies exist to block TF expression and function, with ongoing clinical development.
• Local anti-TF therapies offer a promising localized antithrombotic strategy with improved safety profiles.